U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of ...

The net prices of Ozempic and Wegovy, or the amount that Novo Nordisk is actually paid for the drugs, have dropped substantially since their launch and are expected to fall even further, said Lars ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

FTC files lawsuit against top PBMs and GPOs for alleged anticompetitive practices in inflating insulin prices. Learn about the allegations and responses.

In a landmark move, the FTC filed a lawsuit targeting the “Big Three” PBMs: CVS Health’s Caremark Rx, Cigna’s Express Scripts (ESI), and UnitedHealth Group’s OptumRx. The suit also includes their ...

In a move to address escalating insulin prices, the Federal Trade Commission (FTC) has initiated action against the three ...

The PBMs say out-of-pocket insulin costs have fallen sharply since 2019. The Pharmaceutical Care Management Association, ...

California lawmakers have sent a bill to Gov. Gavin Newsom that aims to rein in the PBMs they say drive up costs and limit ...

Gov. Mike Dunleavy signed a bill Monday that would bring Pharmacy Benefit Managers, or PBMs, under tighter state regulation.